Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.73 |
| ▸ | GFER | P55789 | 1/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2501726 | 0.86 | KMT2A (0.70) | MEN1KMT2AMAPK10GFERHDAC3 | |
| SCHEMBL3279571 | 0.85 | MEN1 (1.00) | MEN1KMT2AMAPK10GFERGAA | |
| SCHEMBL8686406 | 0.82 | MAPK10 (0.58) | MEN1KMT2AMAPK10GFERHDAC3 | |
| SCHEMBL16089597 | 0.82 | MAPK10 (0.58) | MEN1KMT2AMAPK10GFERMAPT | |
| SCHEMBL1518700 | 0.79 | MAPK10 (1.00) | MEN1KMT2AMAPK10GFERHDAC3 | |
| SCHEMBL7677416 | 0.79 | MAPK10 (0.56) | MEN1KMT2AMAPK10GFERHDAC3 | |
| SCHEMBL8401982 | 0.79 | MAPK10 (0.55) | MEN1KMT2AMAPK10GFERHDAC3 | |
| SCHEMBL6832802 | 0.79 | MEN1 (0.55) | MEN1KMT2AMAPK10GFERMAPT | |
| SCHEMBL19024050 | 0.79 | MEN1 (0.55) | MEN1KMT2AMAPK10GFERHDAC3 | |
| SCHEMBL4926590 | 0.79 | MEN1 (0.55) | MEN1KMT2AMAPK10GFERHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172570-A1 | METHOD OF MAKING BENZAZOLES | US GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172570-A1 | METHOD OF MAKING BENZAZOLES | US GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2013-07-04 | — | — | US | disclosed |
| US-7939663-B2 | Phosphor metallic compound and an organic electroluminescence device having improved luminous efficiency and color purity; long lifespan; highly efficient phosphor host material | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-05-10 | — | — | US | disclosed |
| US-20080275239-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SAMSUNG ELECTRONICS CO., LTD., (KR) | 2008-11-06 | — | — | US | disclosed |
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | RANBAXY LABORATORIES LIMITED (IN) | 2008-08-28 | — | — | US | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PFIZER INC | 2004-09-16 | — | — | US | disclosed |
| US-6713482-B2 | SUCH AS (E)-1-(2-PYRIDYL)-2-STYRYL-1H-BENZIMIDAZOLE; ANTIINFLAMMATORY AND ANALGESIC AGENTS; PROSTAGLANDIN INHIBITORS | PFIZER INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | OKUMURA YOSHIYUKI (JP) | 2003-01-16 | — | — | US | disclosed |
| EP-0937722-B1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER (US) | 2002-07-03 | — | — | EP | disclosed |
| US-6310079-B1 | NON-STEROIDAL ANTIINFLAMMATORY AGENTS | PFIZER INC. | 2001-10-30 | — | — | US | disclosed |
| EP-0937722-A1 | Benzimidazole derivatives as cyclooxygenase-2 inhibitors | PFIZER INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0756602-B1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC (US) | 1999-06-30 | — | — | EP | disclosed |
| US-5739129-A | AGONIST ACTIVITY | GLAXO WELLCOME INC. (US) | 1998-04-14 | — | — | US | disclosed |
| CN-1176646-A | CCK or gastrin modulating 5 -heterocyclic-1, 5-benzodiazepines | GLAXO WELLCOME INC (US) | 1998-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207659-A1 | INHIBITORS OF PHOSPHODIESTERASE TYPE 4 | PDE4A, PDE4B, PDE4C | MEN1 4784/4885KMT2A 4487/4885MAPK10 1078/4885 |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | MEN1 4156/4885KMT2A 1555/4885MAPK10 1199/4885 |
| US-20080275239-A1 | Metallic Compound and Organic Electroluminescence Device Comprising the Same | SCO2, NFE2L2, SOD1 | MEN1 108/4885KMT2A 1787/4885MAPK10 1393/4885 |
| US-20130172570-A1 | METHOD OF MAKING BENZAZOLES | NBAS, CBR3, CBR1 | MEN1 2940/4885KMT2A 2290/4885MAPK10 4804/4885 |
| US-20030013886-A1 | Benzimidazole cyclooxygenase-2 inhibitors | PTGS1, CBR1, CBR3 | MEN1 4840/4885KMT2A 1611/4885MAPK10 3836/4885 |
| US-20040181062-A1 | Benzimidazole cyclooxygenase-2 inhibitor | PTGS1, CBR1, CBR3 | MEN1 4821/4885KMT2A 1403/4885MAPK10 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.